

SM



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/018,936	10/19/2001	Salman Baig	235.00270101	8674

26813 7590 06/03/2004

MUETING, RAASCH & GEBHARDT, P.A.  
 P.O. BOX 581415  
 MINNEAPOLIS, MN 55458

EXAMINER

KENEDY, ANDREW A

ART UNIT	PAPER NUMBER
----------	--------------

1631

DATE MAILED: 06/03/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

34-

## Office Action Summary

### Application No.

10/018,936

### Applicant(s)

BAIG ET AL.

### Examiner

Andrew A. Kenedy

### Art Unit

1631

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-48 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-48 are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date ____. | 6) <input type="checkbox"/> Other: ____.  |

## DETAILED ACTION

### *Election/Restrictions*

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1 and 4-7, drawn to a vaccine comprising a cyst wall cysteine proteinase derived from *Taenia solium*.

Group II, claim(s) 2-3 and 4-7, drawn to a vaccine comprising a polynucleotide having a sequence that encodes a cyst wall cysteine proteinase derived from *Taenia solium*.

Group III, claim(s) 8 and 10, drawn to a method for treating an animal harboring *Taenia* infection.

Group IV, claim(s) 9 and 44, drawn to a method for protecting an animal against *Taenia* infection comprising administering a vaccine.

Group V, claim(s) 11-18, drawn to a pharmaceutical composition comprising an inhibitor molecule that inhibits the activity of cyst wall cysteine protease.

Group VI, claim(s) 19-25, 40, 42, 43 and 48, drawn to a method for treating human neurocysticercosis.

Group VII, claim(s) 26-34, drawn to a method for inhibiting *Taenia* cyst wall protease activity.

Group VIII, claim(s) 35-36, drawn to a method for identifying an inhibitor of *Taenia* cysteine proteinase activity.

Group IX, claim(s) 37-39 and 45, drawn to a computer-assisted method for identifying an inhibitor of *Taenia* cysteine proteinase activity.

Group X, claim(s) 41, 46 and 47, drawn to a method for protecting an animal against *Taenia* infection comprising administering a pharmaceutical composition comprising an inhibitor of *Taenia* cysteine proteinase.

Art Unit: 1631

2. Claims 4-7 are drawn to the products of Claims 1-3, and have therefore been included in both Groups I and II. These Claims will be examined only to the extent that they reflect the base method elected. For example, if Group I is elected, then Claims 4-7 will be examined with respect to Claim 1 only.

3. The inventions are distinct, each from the other for the following reasons:

The technical feature linking Groups I-X appears to be that they all relate to a cyst wall proteinase derived from *Taenia solium*.

However, White et al. (*J. Parasitol.*, 78(2), 1992, pp. 281-287), which was cited in the search report of Applicants' PCT application No. US00/10672, teaches isolating all of the cysteine proteinase from *Taenia solium* cysts (see pg. 284, col. 1-2; pg. 281, col. 2, paragraph 1; and the abstract). Therefore, the technical feature linking the inventions of Groups I-X does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

Consequently, Groups I-X are not so linked by a special technical feature and are therefore considered as separate and distinct inventions. Included in Group I is any first appearing method of using, and first appearing method of making, the product of Claim 1.

4. Notice of Rejoinder of Product and Process Claims where applicable.

In any instance where the examiner has required restriction between product and process claims, and applicant elects claims directed to the product where the product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the even of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the

Art Unit: 1631

product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.**

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP 804.01.

***Contact Information***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Andrew A. Kenedy whose telephone number is (571)-272-0574. The examiner can normally be reached on Monday-Friday 9:00am-5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (571)-272-0722. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

A.A.K. May 26, 2004

*Marianne P. Allen*  
MARIANNE P. ALLEN  
PRIMARY EXAMINER 6/1/04  
AU1631